• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Drug & research development » Clinical trials » NCT00966602

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Clinical Trials gov number: NCT00966602

Click on the tabs to move through the sequence.

Purpose: To assess the pharmacokinetics and safety of co-administration of ivacaftor and VX-809 in healthy adults.

Phase: 1

Type: Interventional, randomized, double-blind, parallel assignment

Study sponsor: Vertex Pharmaceuticals Incorporated

  • Body mass index between 18.5 and 30.0 kg/m2, inclusive
  • Subjects of child-bearing potential and who are sexually active must meet contraception requirements
  • Female subject must have a negative serum pregnancy test at screening, Day -1, and throughout the study

Ivacaftor, Lumacaftor

Geographical Location

Number of Participants
≤50 (18-55 years)

Primary Endpoint

  • Pharmacokinetic (PK) parameters of ivacaftor and its metabolites in plasma in the presence and absence of VX-809 (70 days)
  • PK parameters of VX-809 in plasma in the presence and absence of ivacaftor (70 days)

Secondary Endpoint

  • Safety as measured by adverse events, physical examination, and clinically significant changes in laboratory values (hematology, chemistry, coagulation, and urinalysis), electrocardiograms and vital signs (70 days)

Click on the tabs to move through the sequence.

  • Experimental: Treatment Period 1

    VX-809 capsule, once daily for 14 days

     Matching Placebo

  • Experimental: Treatment Period 2

     VX-770 tablet, once every 12 hours for 14 days

     Matching Placebo

  • Experimental: Treatment Period 3

     VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days

     Matching Placebo

View Trial Results